



**Enzymatica**  
THE SCIENCE THAT PROTECTS

# Interim Report Q2/2023

January–June 2023

Enzymatica AB develops and sells health products mainly to treat diseases and symptoms in the upper respiratory tract. The products are based on a barrier technology that includes marine enzymes with unique properties. The company's first product is the medical device product ColdZyme®, a mouth spray for colds. The product has been launched in over 30 markets on four continents. The strategy is to continue to grow by developing more health products, strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. Enzymatica's certified advisor is Erik Penser Bank. For more information, please visit [www.enzymatica.com](http://www.enzymatica.com).

# Enzymatica AB (publ)

## Interim report, January–June 2023

Q2	H1
<ul style="list-style-type: none"> <li>Net sales reached SEK 8.8 (9.6) million.</li> <li>The operating result totaled SEK -11.2 (-15.9) million.</li> <li>Earnings per share, basic and diluted, were SEK -0.07 (-0.10).</li> <li>Cash flow from operating activities totaled SEK -9.5 (-21.5) million.</li> </ul>	<ul style="list-style-type: none"> <li>Net sales reached SEK 21.8 (13.8) million.</li> <li>The operating result totaled SEK -25.5 (-34.0) million.</li> <li>Earnings per share, basic and diluted, were SEK -0.16 (-0.22).</li> <li>Cash flow from operating activities totaled SEK -21.7 (-31.7) million.</li> </ul>

***“Discussions on launches in some of the world’s largest cold markets intensified during the first half of the year. In the near future, we also expect results from two key scientific studies.”***

Claus Egstrand, CEO

### Key figures

(SEK million)	Q2 2023	Q2 2022	H1 2023	H1 2022	Full year 2022
Net sales	8.8	9.6	21.8	13.8	48.9
Gross margin, %	63	52	62	53	58
Operating profit/loss	-11.2	-15.9	-25.5	-34.0	-68.2
Cash flow from operating activities	-9.5	-21.5	-21.7	-31.7	-65.4
Net cash			6.5	-5.2	28.4
Average number of employees	21	23	22	23	23



# Enzymatica AB (publ)

## Interim report, January–June 2023

---

### Significant events during the quarter

- No significant events were reported during the quarter.

### Significant events after the quarter

- No significant events were reported after the end of the quarter.

---

### Other events during and after the quarter

- The University of Kent, UK, conducted a clinical study starting in November 2022 to investigate ColdZyme's effects *in vivo* among elite athletes in endurance sports such as cycling and long-distance running. The results of the placebo-controlled, double-blind, and randomized study are expected in August 2023.
- The Medical University of Innsbruck, Austria, conducted an *in vitro* study during the second quarter to explore the effect of ColdZyme on human cells infected with influenza virus. The study results are expected in August 2023.

### Impact of external events on business

After having had a major negative impact on Enzymatica's sales in 2021 and 2022, the coronavirus pandemic does no longer have any substantial impact on operations.

Russia's attack on Ukraine has created uncertainty in many markets, along with a sharply deteriorated economic situation in many countries. So far, Enzymatica has not seen any major impact on its operations due to the change in interest rates or the economic downturn. Ukraine was one of the markets where Enzymatica planned to launch, and this work will resume when circumstances permit.



CEO Claus Egstrand:

## An exciting and important time ahead



*During the spring and early summer, discussions intensified about launching and relaunching in some of the world's largest cold remedy markets, now that the pandemic lies behind us. In the near future, we also expect results from two key scientific studies.*

The first half of 2023 showed a growth of 58% compared to the same period last year. It is a clear sign of us being on the right track, although there is a long way ahead of us before we reach our financial targets at the end of 2026.

The second quarter is always the weakest of the year for us, as it is the period when the number of colds is the lowest. In the future, when we are established in more markets in the southern hemisphere, seasonal variations will likely even out somewhat since the cold season is different there.

### **Intensified discussions about expansion**

Still, the second quarter was an intensive period in many ways. After the pandemic, there has been an increase in consumer knowledge about the importance of protecting against viruses, which should benefit ColdZyme. In the first quarter of 2023, we saw very positive effects in Sweden when we reinforced our own marketing in TV and digital. Together with our partners, we now must increase the visibility of our product in considerably more countries. Therefore, we have a current dialogue with our two largest partners STADA and Sanofi where we jointly assess the ambitions for each market for the virus season 2023/24.

Accordingly, authorities have also returned to more normal operations and because of that we have been able during the spring to intensify the registration process for our product in Japan and China. In parallel, we plan long-term for launches in other large cold markets – a vital part of our work to reach our financial goals by the end of 2026.

### **Study results in August**

We are entering a very exciting period for Enzymatica. In August, we expect to receive the results of two scientific studies, both of which can provide important insights into our barrier technology and our product. The Medical University of Innsbruck is conducting an *in vitro* study on how human cells infected with the influenza virus react when treated with ColdZyme. A clinical trial is underway at the University of Kent in which elite athletes are using a placebo or ColdZyme to treat the first signs of an upper respiratory tract infection.

These two studies are part of our long-term research program to gain more knowledge into our barrier technology and how our product can be used.

### **A potential new role for our technology**

We already know that our product could protect against certain coronaviruses, even if they were common cold viruses. Given the pandemic and the growing insight about the importance of a broader protection against viruses, we have decided to focus not just on cold viruses, but to consider the big picture of upper respiratory viruses as a whole. Our focus, with our expertise in viruses and enzymes, is to complement traditional vaccines and offer consumers a way to protect themselves against viruses.

Against this background, we launched our research program where we are collaborating with two universities, along with conducting our own studies. We wanted to move away from

our focus on the cold alone and think more broadly given the major changes we saw in the world around us.

### **An exciting time ahead**

We know from consumer surveys that 9 out of 10 people who test our product say they will buy it again. Loyal consumers are indeed gratifying, but our main challenge is to reach new consumers worldwide. We have a product that is easy to understand, easy to bring along, and provides a practical benefit in everyday life. These insights, along with the knowledge gained from the scientific studies, will serve as the foundation of our business over the next few years.

We are moving from the damaged self-confidence that naturally characterized the organization when the pandemic hit hardest to facing the market with high ambitions and a broader positioning for our product. We create growth together with our partners in both existing and new countries once the market returns to normal. The second half of 2023 is going to be a very exciting time for Enzymatica.

Claus Egstrand, CEO



## Enzymatica at a glance

Enzymatica's business concept is to develop self-care products, based on the company's barrier technology platform. The company was founded in 2007, has its head office in Lund, Sweden, and has been listed on the Nasdaq First North Growth Market since 2015.

Enzymatica has developed ColdZyme, a unique mouth spray for colds. It is sold on more than 30 markets on four continents and distributor agreements are in place for about 30 more countries.

Sales are handled in Sweden and the UK through contract organizations and in other markets through partner agreements with leading players in consumer healthcare, such as French Sanofi and German STADA. These distributors usually sell the product under their own brands, such as ViruProtect (STADA) and Bisolviral (Sanofi). In addition to ColdZyme, in Germany, since early 2020 STADA has sold a spray for improved oral health, StadaProtect, which was developed by Enzymatica based on the same barrier technology platform.

Enzymatica's development work is focused on products related to upper respiratory tract infections. Research and development is led from Lund, in close collaboration with the production facility in Iceland.

### Seasonal variations


Cold products usually have a seasonal peak in the winter in the northern hemisphere, while sales level out in the summer months. During the coronavirus pandemic, sales were low even in the winter months due to social distancing, leading to a lower spread of the cold virus.

### Financial targets

In November 2021, the Board set financial targets for Enzymatica for the next five years. At the end of 2026, sales will amount to at least SEK 600 million, with an EBIT margin of at least 28%. The strong growth compared with current sales is expected to result from launching in new major markets such as China, Japan and the US, as well as by achieving increased market share in existing core markets, including Sweden, the UK, Germany, Italy and France.

### New markets

Following delays due to the pandemic, the company is now engaged in constructive dialogue with its partners in China and Japan. It is estimated that the product can be launched in these two markets within one or two years. In 2023, discussions were initiated with a potential partner for the North American markets. In the UK, Enzymatica is looking for a new partner to step up sales and marketing efforts.



- Product launched
- Launch planned within the next few years



## Financial overview – April-June 2023

### Sales and market

Consolidated net sales in the second quarter of 2023 came in at SEK 8.8 (9.6) million – a 9% year-on-year decrease compared with the same period in 2022.

A clear increase in end-consumer demand can be seen both in Sweden and in Enzymatica's partner markets. Sales in the second quarter were 38% higher than the same period in 2019, which was the last year when sales were not affected by the pandemic.

The cold remedy market at pharmacies in Sweden increased 2,0% in value for the quarter compared with the same quarter in 2022. In the same period, ColdZyme sales from pharmacies increased by 10,3% in value compared with 2022. ColdZyme's share of the total cold remedy market in terms of value was 4,0%, compared with 3,8% for the same period year-on-year. In the UK, sales increased during the quarter. At Boots, ColdZyme's sales increased by 10,2% compared with the same quarter in 2022. At amazon.co.uk, sales increased by 17,0% during the quarter compared with the same quarter in 2022.

### Performance

The gross margin during the quarter was 63% (52). Enzymatica has experienced variations in gross margins between individual quarters, which is due to the distribution between its own sales and sales via partners. Total operating expenses for the quarter amounted to SEK 17.0 (21.3) million. The lower costs can be attributed to lower administrative expenses and research and development costs compared with the same period last year. No expenses for development projects were capitalized during the quarter (0).

The consolidated operating loss was SEK -11.2 (-15.9) million. Net financial income and expenses for the period amounted to SEK -0.4 (0.1) million. Tax expense for the period was SEK 0.1 (0.4) million. Impairment charges totaled SEK 1.6 (0.9) million.

### Research, development, and other investments

Total consolidated research and development expenses in the Group were in line with the plan and amounted to SEK 3.6 (8.8) million for the second quarter. The Group's investments in property, plant and equipment and intangible assets for the quarter totaled SEK 1.0 (2.7) million, of which SEK 0 (0) million are intangible assets.

In November 2022, the University of Kent (UK) initiated a double-blind, placebo-controlled clinical study to explore the effects of ColdZyme on upper respiratory tract infections in elite athletes. The study builds on a previous 2020 study from the same research group, which showed that treatment with ColdZyme can reduce the number of lost training days. The study was initiated by University of Kent and the results are expected in August 2023.

The Medical University of Innsbruck, Austria, conducted an *in vitro* study during the second quarter to explore the effect of ColdZyme on human cells infected with the influenza virus. The study is an important addition to previous studies from the same research group. They then explored how ColdZyme stops different types of viruses from adhering to human cells, while the current study investigates the effect of ColdZyme on already infected cells. The study results are expected in August 2023.



## Financial overview – January-June 2023

### Sales

Consolidated net sales in the first half of the year came in at SEK 21.8 (13.8) million – a 58% year-on-year increase compared with the same period in 2022.

### Performance

Gross margin in first half of the year was 62% (53).

Total operating expenses for the first half of the year were SEK 39.5 (42.0) million. No expenses for development projects were capitalized during the period SEK 0 (0) thousand.

The consolidated operating loss was SEK -25.5 (-34.0) million.

The result for the period was SEK -26.4 million (-33.4).

### Funding and cash flow

The Group's available funds at the end of the period totaled SEK 30.7 (5.7) million, of which SEK 29.1 (5.0) million were in cash and cash equivalents and SEK 1.6 (0.7) million in unutilized credit facilities.

In June 2022, Enzymatica's three largest shareholders, along with the CEO and chairman of the board, entered into a loan agreement with the company for a maximum of SEK 20 million, which has been fully utilized.

Net cash at the end of the period totaled SEK 6.5 (-5.2) million. Cash flow from operating activities from January through June 2023 totaled SEK -21.7 (-31.7) million. Cash flow includes a one-off payment of SEK 5.6 million to one of the company's partners. Total cash flow for the period amounted to SEK -21.7 (-26.7) million.



### Parent company

The parent company is responsible for group management and all operational activities, with the exception of enzyme production and the part of research and development that take place within the subsidiary Zymetech.

The parent company's sales for the first half of 2023 reached SEK 20.2 (15.1) million. Result before tax came in at SEK -27.3 (-32.3) million. The parent company's investments in property, plant & equipment and intangible assets for the first half of the year totaled SEK 0 (0) million and cash flow was SEK -22.2 (-25.2) million. Please see the consolidated figures for more information.

### Staff

The number of people employed by the group, converted to full-time positions, was 21 (23) at the end of the period. The employees included 10 (9) men and 11 (14) women.



## Other information

### Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the subsidiaries Zymetech ehf (corporate identity no. 6406830589), with its head office in Reykjavik, Iceland, and Enzymatica Care AB (corporate identity no. 556701-7495), with its head office in Lund, Sweden.

### Accounting policies

This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in compliance with the International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. The parent company's financial statements have been prepared in compliance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. Disclosures in accordance with IAS 34.16A are incorporated in the financial statements and its accompanying notes, as well as in other parts of this interim report. The recognition and measurement policies applied in the 2022 Annual Report have been applied in this interim report as well.

### Segment reporting

Enzymatica's operations currently include only one operating segment: Medical devices. Please see the income statement and balance sheet for reporting on this operating segment.

### Audit

This report was not reviewed by the Company's auditors.

### Related-party transactions

In June 2022, a loan agreement for SEK 20 million was signed with Enzymatica's three largest owners – Mats Andersson (SEK 5 million), Håkan Roos (SEK 5 million) and Björn Algkvist (SEK 5 million) – as well as Chairman of the Board Bengt Baron (SEK 3 million) and CEO Claus Egstrand (SEK 2 million). Mats Andersson, Bengt Baron, and Claus Egstrand are related parties with respect to the company. The utilized loan amount must be repaid starting September 30, 2024, and be repaid in full by March 30, 2025, at the latest. The loan runs at an annual interest rate of STIBOR 3 months + 7 percent. The loan amount has been fully utilized.

### Information about risks and uncertainties

Enzymatica's business is exposed to several risks, both operational and financial risks. The operational risks mainly comprise uncertainty related to product development, supplier agreements, competition, regulatory permits, product liability, dependency on key personnel, legislation and regulatory requirements, intellectual property, and distribution, as well as the impact of the coronavirus pandemic. The financial risks mainly comprise currency, credit, funding, and liquidity risks. For a more detailed description of the risks and uncertainties Enzymatica faces, please see the 2022 Annual Report, which is available on the company's website.

Enzymatica is monitoring developments related to the war in Ukraine and the consequences of the extensive economic sanctions against Russia. Both countries are markets where Enzymatica had previously planned to launch over the next

few years, but a delayed launch, or the lack thereof, would not affect Enzymatica's business or the approved financial targets.

Enzymatica is affected by the economic uncertainty in the world, with respect to rising inflation, higher interest rates, and climbing costs for transports, energy, equipment, and materials. However, the impact on the company has been marginal as of the end of the second quarter of 2023.

### Upcoming financial information

Interim report, Jan–Sep 2023	November 7, 2023
Year-end report 2023	February 16, 2024

The interim reports and annual report are available on Enzymatica's website [www.enzymatica.se](http://www.enzymatica.se).



## Other information

The Board of Directors and CEO hereby confirm that this year-end report provides a true and fair view of the parent company's and group's business, financial position and results of operations, and describes material risks and uncertainties faced by the parent company and group companies.

Lund, July 18, 2023

Bengt Baron  
Chairman of the Board

Helene Willberg  
Board member

Guðmundur Pálmason  
Board member

Moa Fransson  
Board member

Mats Andersson  
Board member

Louise Nicolin  
Board member

Claus Egstrand  
CEO

### For questions about this report, please contact:

Claus Egstrand, CEO, Enzymatica AB  
+44 7780 22 8385 | [claus.egstrand@enzymatica.com](mailto:claus.egstrand@enzymatica.com)

Therese Filmersson, CFO, and Deputy CEO, Enzymatica AB  
+46 (0) 708 40 72 24 | [therese.filmersson@enzymatica.com](mailto:therese.filmersson@enzymatica.com)

### Publication

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on Tuesday, July 18, 2023.

### Street address

Enzymatica AB (publ), corp. ID no. 556719-9244.

Mailing address: Ideon Science Park, 223 70 Lund, Sweden

Street address: Scheelevägen 19, Ideon, Lund, Sweden

Tel: +46 (0)46 286 31 00 | [info@enzymatica.se](mailto:info@enzymatica.se) |

[www.enzymatica.se](http://www.enzymatica.se)

Enzymatica is listed on the Nasdaq First North Growth Market. The Company is traded under the ticker symbol ENZY and ISIN code SE0003943620. Enzymatica's certified advisor is Erik Penser Bank.



## Condensed consolidated statement of comprehensive income

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
<b>Operating income</b>					
Net sales	8 764	9 623	21 802	13 785	48 948
Cost of goods sold	-3 285	-4 622	-8 384	-6 541	-20 494
<b>Gross profit</b>	<b>5 479</b>	<b>5 001</b>	<b>13 418</b>	<b>7 243</b>	<b>28 454</b>
Sales & Marketing expenses	-3 751	-2 854	-13 595	-10 508	-32 784
Administrative expenses	-9 660	-9 700	-18 806	-17 735	-38 716
Research and development costs	-3 622	-8 795	-7 133	-13 776	-26 497
Other operating income	673	792	1 101	1 421	2 629
Other operating costs	-274	-330	-520	-678	-1 304
<b>Operating profit/loss</b>	<b>-11 155</b>	<b>-15 886</b>	<b>-25 535</b>	<b>-34 032</b>	<b>-68 217</b>
<b>Profit/loss from financial items</b>					
Interest income and similar profit/loss items	156	307	239	454	760
Interest expenses and similar profit/loss items	-567	-135	-1 011	-245	-1 289
<b>Profit/loss after financial items</b>	<b>-11 566</b>	<b>-15 713</b>	<b>-26 307</b>	<b>-33 823</b>	<b>-68 746</b>
Tax expenses	55	351	-124	412	89
<b>Profit/loss for the period</b>	<b>-11 511</b>	<b>-15 362</b>	<b>-26 431</b>	<b>-33 411</b>	<b>-68 657</b>
<b>Other comprehensive income:</b>					
Items that have been redirected or may be included in the profit/loss:					
Translation difference of subsidiaries	785	911	1 466	1 709	1 013
<b>Total other comprehensive income, net of tax</b>	<b>785</b>	<b>911</b>	<b>1 466</b>	<b>1 709</b>	<b>1 013</b>
<b>Total comprehensive income for the period</b>	<b>-10 726</b>	<b>-14 451</b>	<b>-24 965</b>	<b>-31 702</b>	<b>-67 644</b>
Share attributable to parent company shareholders	-10 726	-14 451	-24 965	-31 702	-67 644



## Earnings per share

	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Earnings per share, SEK (basic and diluted)	-0,07	-0,10	-0,16	-0,22	-0,44
Equity per share, SEK	0,62	0,62	0,62	0,62	0,77
Equity-asset ratio, %	71%	72%	71%	72%	72%
Number of outstanding shares	164 256 840	149 324 400	164 256 840	149 324 400	164 256 840
Average number of outstanding shares (basic and diluted)	164 256 840	149 324 400	164 256 840	149 324 400	154 301 880

## Key financial indicators

### Earnings per share

Profit/loss for the period in relation to average weighted number of shares.

### Equity per share

Equity in relation to number of shares at the end of the period.

### Equity ratio

Equity in relation to total assets.

### Net cash

Interest-bearing current and non-current liabilities, less cash and cash equivalents.



## Quarterly review by auditors

All amounts in SEK thousand	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Net sales	8 764	13 038	16 635	18 528	9 623
Gross profit/loss	5 479	7 939	10 919	10 292	5 001
Gross margin in %	63%	61%	66%	56%	52%
Operating costs	-17 033	-22 501	-32 462	-23 517	-21 348
Operating profit/loss	-11 155	-14 380	-21 574	-12 611	-15 886
Profit/loss for the period	-11 511	-14 920	-22 183	-13 064	-15 362
Cash flow	-9 389	-12 285	-28 697	74 481	-15 344



## Condensed consolidated statement of financial position

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
<b>Assets</b>				
Intangible assets	69 589	72 915	70 218	70 847
Tangible assets	15 855	17 601	16 242	16 401
Financial assets	2 335	2 730	2 206	2 315
Inventories	13 383	13 217	11 217	11 511
Trade receivables	6 818	12 709	9 783	14 229
Other receivables	6 482	6 282	4 136	8 420
Cash and cash equivalents	29 119	4 968	38 422	50 689
<b>Total assets</b>	<b>143 582</b>	<b>130 422</b>	<b>152 224</b>	<b>174 413</b>
<b>Equity and liabilities</b>				
Equity	101 327	93 270	112 053	126 293
Long-term interest-bearing liabilities	21 954	8 020	21 495	21 120
Current interest-bearing liabilities	696	2 149	972	1 195
Trade payables	2 020	5 714	3 071	6 671
Other liabilities	17 585	21 269	14 633	19 134
<b>Total equity and liabilities</b>	<b>143 582</b>	<b>130 422</b>	<b>152 224</b>	<b>174 413</b>

## Condensed consolidated statement of changes in equity

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
Opening balance	126 293	124 972	126 293	124 972
New share issue	0	0	0	74 662
Issue expenses related to New share issue	0	0	0	-5 698
Total comprehensive income for the period	-24 965	-31 702	-14 240	-67 644
<b>Closing balance</b>	<b>101 327</b>	<b>93 270</b>	<b>112 053</b>	<b>126 293</b>



## Condensed consolidated statement of cash flows

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
Operating profit/loss	-11 155	-15 886	-25 535	-34 032	-68 217
Adjustments for non-cash items	Note 1 1 510	1 449	2 890	3 061	7 733
Financial items	-411	173	-772	209	-529
<b>Cash flow from operating activities before changes in working capital</b>	<b>-10 056</b>	<b>-14 264</b>	<b>-23 417</b>	<b>-30 762</b>	<b>-61 014</b>
Changes in working capital	522	-7 251	1 723	-937	-4 428
<b>Cash flow from operating activities</b>	<b>-9 534</b>	<b>-21 515</b>	<b>-21 694</b>	<b>-31 698</b>	<b>-65 441</b>
Acquisition/disposal of property, plant & equipment	-37	-1 299	-314	-2 537	-3 717
<b>Cash flow from investing activities</b>	<b>-37</b>	<b>-1 299</b>	<b>-314</b>	<b>-2 537</b>	<b>-3 717</b>
Rights Issue	0	0	0	0	74 662
Transaction costs attributable to new share issue	0	0	0	0	-5 698
Change in bank/overdraft facilities	182	7 469	334	7 534	19 276
<b>Cash flow from financing activities</b>	<b>182</b>	<b>7 469</b>	<b>334</b>	<b>7 534</b>	<b>88 241</b>
<b>Total cash flow for the period</b>	<b>-9 389</b>	<b>-15 344</b>	<b>-21 674</b>	<b>-26 701</b>	<b>19 083</b>
Cash and cash equivalents at start of period	38 422	20 350	50 689	31 619	31 619
Translation difference cash and cash equivalents	86	-37	104	49	-13
<b>Cash and cash equivalents at end of period</b>	<b>29 119</b>	<b>4 968</b>	<b>29 119</b>	<b>4 968</b>	<b>50 689</b>

Note 1: Primarily related to depreciation.



## Parent company income statement

All amounts in SEK thousand	Apr-Jun 2023	Apr-Jun 2022	Jan-Jun 2023	Jan-Jun 2022	Jan-Dec 2022
<b>Operating income</b>					
Net sales	8 458	10 410	20 237	15 123	46 354
Cost of goods sold	-5 437	-6 999	-12 482	-11 468	-30 061
<b>Gross profit</b>	<b>3 021</b>	<b>3 411</b>	<b>7 756</b>	<b>3 656</b>	<b>16 292</b>
Sales & Marketing expenses	-3 459	-2 674	-12 952	-9 919	-31 726
Administrative expenses	-6 338	-6 777	-12 656	-12 239	-26 547
Research and development costs	-4 535	-8 642	-8 970	-14 381	-27 674
Other operating income	1 061	421	728	880	1 182
Other operating costs	-921	-325	-514	-672	-1 238
<b>Operating profit/loss</b>	<b>-11 172</b>	<b>-14 585</b>	<b>-26 608</b>	<b>-32 675</b>	<b>-69 711</b>
<b>Profit/loss from financial items</b>					
Interest income and similar profit/loss items	169	300	283	444	704
Interest expenses and similar profit/loss items	-555	-32	-969	-56	-872
<b>Profit/loss after financial items</b>	<b>-11 558</b>	<b>-14 317</b>	<b>-27 293</b>	<b>-32 287</b>	<b>-69 878</b>
Tax expenses	0	0	0	0	-196
<b>Profit/loss for the period</b>	<b>-11 558</b>	<b>-14 317</b>	<b>-27 293</b>	<b>-32 287</b>	<b>-70 074</b>



## Parent company balance sheet

All amounts in SEK thousand	2023-06-30	2022-06-30	2023-03-31	2022-12-31
<b>Assets</b>				
Intangible assets	7 283	10 608	7 912	8 541
Tangible assets	78	170	105	131
Financial assets	18 452	18 648	18 452	18 452
Inventories	10 737	10 270	8 121	8 437
Trade receivables	6 516	12 428	9 367	13 704
Receivables from group companies	2 002	4 186	444	2 585
Other receivables	4 134	2 540	4 158	6 802
Cash and bank balances	26 819	4 895	36 665	49 009
<b>Total assets</b>	<b>76 022</b>	<b>63 745</b>	<b>85 224</b>	<b>107 662</b>
<b>Equity and liabilities</b>				
Equity	35 824	31 940	47 382	63 117
Long-term interest-bearing liabilities	21 779	7 216	21 266	20 875
Current interest-bearing liabilities	0	0	0	0
Liabilities to group companies	0	0	0	0
Trade payables	1 863	5 457	2 696	5 972
Other liabilities	16 556	19 133	13 880	17 698
<b>Total equity and liabilities</b>	<b>76 022</b>	<b>63 745</b>	<b>85 224</b>	<b>107 662</b>





[www.enzymatica.com](http://www.enzymatica.com)